GLG News by Dermatologists (US)
Articles with lock require a subscription to GLG News |
Request a free trial
April 1, 2008Long term use of Allergan's Botox does not decrease efficacy
Analysis of: Efficay of Bolinum toxin does not sag over time | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that it lays to rest a misconception that long term repeated use of Botox ( Allergan) leads to decreased efficacy. Efficacy was maintained, and no neutralizing antibodies were found to Botox. This will reassure most users of Botox, and patients as well.
April 1, 2008Serious Skin Reactions with TNF antagonists
Analysis of: Serious Skin Reactions with TNF antagonists | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that it defined the incidence of serious skin reactions to the three common TNF antagonists- Enbrel, Humira, and Remicade. The incidence is relatively low in comparison to the numbers of patients treated. Any foreign protein has the potential for eliciting these reactions,...
March 31, 2008AN2728 phase 2a results encouraging.
Analysis of: Anacor Pharmaceuticals Announces Positive Results from Phase 2A Clinical Trial of AN2728 in Psoriasis Patients | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Anacor's recent release of the data from their phase 2a study of AN 2728 for psoriasis were encouraging. Over 69% actively treated plaques of psoriasis improved versus only 6% of placebo treated plaques. The study was limited by the short duration- only 28 days versus up to 16...
March 31, 2008Psoriasis associated with comorbidities- Is this to be expected?
Analysis of: Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions | www.pharmalive.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that it is one of the first to confirm what is a widely held belief among many dematologists who treat many patients with psoriasis. Specifically that these patients suffer a higher rate of cardiovascular diseases, depression, malignancy, etc. This makes perfect...
March 19, 2008Ustekinumab shows promise
Analysis of: Novel Biologic Agent Proves Highly Effective in Severe Plaque Psoriasis | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Centocors new product- Ustekinumab /CNTO 1275 had impressive results in the recent PHOENIX trials and the application is under review at the FDA. The PASI score reductions are superior to the exiting agents such as Enbrel and Humira, and are comparable to those of the other Centocor product- Remicade...
March 7, 2008Renovo's Juvista product holds promose
Analysis of: Juvista Phase II Trial Results in Scar Revision and Breast Augmentation Surgery | www.renovo.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that this is an under served market. Current scar reduction products are only modestly effective, or not effective at all. An agent which has a "70% "reported reduction in scar appearance,is safe, and only has to be used a few times has a large market and will be successful....
March 6, 2008Phosphagenics Topical Retinoic Acid Clinical Trial Initiated
Analysis of: Phosphagenics Initiates US Clinical Trials For Its Topical Retinoic Acid | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This new delivery system from Phosphagenics for enhancing absorption and reducing irritation will have moderate effect on the retinoid market. Retinoic Acid use has been in decline not so much because of irritation, but because of the introduction of more efficacious retinoids like Tazorac and Differin...
February 13, 2008
Fears of safety and fears of a black box warning.
Analysis of: FDA Issues Warning About Botox Deaths | www.pharmalot.com
Author: GLG Expert Contributor
Fears of safety and fears of a black box warning.Analysis of: FDA Issues Warning About Botox Deaths | www.pharmalot.com
Author: GLG Expert Contributor
Is Botox as safe as we have imagined it to be? The implications of an impending possible black box warning on the cosmetic and medical use of Botox in dermatology.
February 12, 2008FDA Botox warning unlikely to limit cosmetic use
Analysis of: FDA Issues Warning About Botox Deaths | www.pharmalot.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The recent FDA warning on Botox is unlikely to limit the cosmetic use of the product because the dose is relatively low. The warning only applies to significantly higher doses in patients with neuromuscular conditions like cerebral palsy. Serious adverse events like allergic reactions are very...
February 8, 2008Botox competitors to make market interesting
Analysis of: Efficacy of Botulinum Toxin Does Not Sag Over Time | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Botox is highly effective cosmetic product, albeit not long lasting. Patient satisfaction is high, and the cost is still not prohibitive. However the predictable and not always justified increases in price have forced many physicians to eagerly await the newer agents. The include products from...
Previous Page : 1 2 3 4 5 6 7 8 9 10 Next21 to 30 of 97
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Heart Stents No Better Than Drugs for Chest Pain Over Time
www.bloomberg.com
UK Says Kidney Cancer Drugs Are Too Pricey
www.pharmalot.com
FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta
www.fda.gov
Abbott signs deal to promote Crestor in U.S.
www.chicagotribune.com
Majority of Patients Want Doc to use EHRs: Study
www.modernhealthcare.com
Byetta sale will reduce after FAD alert
August 19, 2008
Less and less evidence to favor coronary stenting
August 15, 2008
Random finding does justify change in Byetta prescribing
August 11, 2008
Fair or Unfair Decision: the cost of the drugs for kidney cancer is more than the economy can bear.
August 11, 2008
byetta / LAR will be multi-billion dollar drug
August 8, 2008